Recent advances in pharmacotherapy for heart failure with reduced ejection fraction (HFrEF) have now afforded multiple, highly efficacious, life-prolonging treatments for this high-risk population.

Over the past 10 years, we have witnessed the unprecedented and rapid revolution of aortic valve replacement (AVR) due to the introduction of a disruptive technology—transcatheter aortic valve replacement (TAVR). Supported by expertly conducted landmark clinical trials by multiple device manufacturers, the speed with which care for severe, symptomatic aortic stenosis (AS) has been transformed has been astonishing.

The most appropriate diagnostic algorithm for patients with stable coronary artery disease (CAD) is still an unresolved matter of debate.

The final luminal cross-sectional area at the ostium of the side branch may predict the outcome of 2-stent techniques, provided the main branch luminal cross-sectional area is kept optimal.

Identification of more than moderate secondary (functional) tricuspid regurgitation (TR) in a patient with severe, symptomatic aortic stenosis (AS) who is a candidate for transcatheter aortic valve replacement (TAVR) is not unusual.